Alectinib

A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States

Cummings AL, Sussell J, Rosettie KL, El Moustaid F, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A Cost-effectiveness Analysis of Adjuvant Alectinib[...]

By afschroeder • October 10, 2025

A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer

Cummings AL, Sussell J, Rosettie KL, Moustaid FE, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A treatment-impact model of alectinib for the[...]

By afschroeder • August 15, 2025